-
公开(公告)号：EP2794650B1
公开(公告)日：2019-08-14
申请号：EP12808642.8
申请日：2012-12-17
申请人： Amgen Inc.
发明人： SUN, Jeonghoon , HAN, Seog Joon , HARRIS, Susie M. , KETCHEM, Randal R. , LU, Ji , MICHAELS, Mark L. , RETTER, Marc W. , TSAI, Mei-Mei
IPC分类号： C07K16/00
-
公开(公告)号：EP2970484B1
公开(公告)日：2018-05-16
申请号：EP14722862.1
申请日：2014-03-13
申请人： Amgen Inc.
CPC分类号： C07K16/30 , C07K16/2803 , C07K16/2809 , C07K2317/31 , C07K2317/35 , C07K2317/55 , C07K2317/565 , C07K2317/60 , C07K2317/626 , C07K2317/64 , C07K2317/73 , C07K2317/94
摘要： Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.
-
公开(公告)号：EP2970477A2
公开(公告)日：2016-01-20
申请号：EP14717954.3
申请日：2014-03-14
申请人： Amgen Inc.
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/00 , C07K16/28 , C07K16/2803 , C07K16/2809 , C07K16/32 , C07K16/40 , C07K16/468 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/60 , C07K2317/622 , C07K2317/64 , C07K2317/71 , C07K2317/73 , C07K2317/92 , C07K2319/00
摘要： Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.
摘要翻译： 本文描述的是含有Fc多肽链和免疫球蛋白可变区的双特异性分子。 还提供了包含这种分子的药物制剂，编码这种分子的核酸，含有这种核酸的宿主细胞，制备这种分子的方法，以及使用这种分子的方法。
-
公开(公告)号：EP2358749B1
公开(公告)日：2018-07-18
申请号：EP09748878.7
申请日：2009-10-08
申请人： Amgen, Inc
发明人： WALKER, Kenneth W. , GEGG, Colin, V., Jr. , HECHT, Randy I. , BELOUSKI, Edward J. , LI, Yue-Sheng , MICHAELS, Mark L. , XU, Jing , ELLISON, Murielle M.
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides comprising extended in vivos half-lives, pharmaceutical compositions comprising FGF21 mutant polypeptides having extended in vivos half lives, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：EP2970484A1
公开(公告)日：2016-01-20
申请号：EP14722862.1
申请日：2014-03-13
申请人： Amgen Inc.
CPC分类号： C07K16/30 , C07K16/2803 , C07K16/2809 , C07K2317/31 , C07K2317/35 , C07K2317/55 , C07K2317/565 , C07K2317/60 , C07K2317/626 , C07K2317/64 , C07K2317/73 , C07K2317/94
摘要： Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.
摘要翻译： 本文提供了可以通过免疫效应细胞介导靶细胞的细胞分裂的异二聚体双特异性抗体，编码此类抗体的核酸，制备此类抗体的方法以及使用此类抗体的方法。 这些抗体包含两个不同的多肽链，每条链包含两个免疫球蛋白可变区和任选的半衰期延长部分。
-
6.发明公开
公开(公告)号：EP4351722A1
公开(公告)日：2024-04-17
申请号：EP22741092.5
申请日：2022-06-09
申请人： Amgen Inc.
发明人： BATES, Darren L. , LIU, Zhi , LEE, TaeWeon , MICHAELS, Mark L. , WANG, Zhulun
IPC分类号： A61P9/10 , C07K14/475
CPC分类号： C07K14/4756 , A61P9/10
-
公开(公告)号：EP3733710A1
公开(公告)日：2020-11-04
申请号：EP20165091.8
申请日：2014-09-25
申请人： Amgen, Inc
发明人： MICHAELS, Mark L. , BORGES, Luis G. , YAN, Wei
摘要： Described herein is a dimeric, bispecific antibody format. Each polypeptide chain of the dimer comprises an immunoglobulin variable region, an immunoglobulin constant region, an Fc polypeptide chain, another immunoglobulin variable region, and another immunoglobulin constant region. Also described are methods of making and using such antibodies.
-
公开(公告)号：EP3197916A2
公开(公告)日：2017-08-02
申请号：EP15775509.1
申请日：2015-09-24
申请人： Amgen Inc.
IPC分类号： C07K16/28 , C07K14/725 , C07K16/32 , C07K16/46 , A61P35/00
CPC分类号： C07K16/468 , C07K14/7051 , C07K16/2809 , C07K16/32 , C07K2317/31 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/92 , C07K2319/00 , C07K2319/50
摘要： Described herein are protease-activatable proteins (PABPs), which, when activated, can mediate cytolysis of target cells by effector cells. Also provided are nucleic acids encoding such PABPs and methods of making and using PABPs.
摘要翻译： 本文描述了蛋白酶活化蛋白质（PABP），其在被激活时可以介导效应细胞对靶细胞的细胞溶解。 还提供了编码这种PABP的核酸以及制备和使用PABP的方法。
-
9.发明公开VARIANT FC-POLYPEPTIDES WITH ENHANCED BINDING TO THE NEONATAL FC RECEPTOR 审中-公开FC-POLYPEPTIDVARIANTEN MIT VERBESSERTER BINDUNG AN DEN NEONATALEN FC-REZEPTOR
公开(公告)号：EP2794650A1
公开(公告)日：2014-10-29
申请号：EP12808642.8
申请日：2012-12-17
申请人： Amgen Inc.
发明人： SUN, Jeonghoon , HAN, Seog Joon , HARRIS, Susie M. , KETCHEM, Randal R. , LU, Ji , MICHAELS, Mark L. , RETTER, Marc W. , TSAI, Mei-Mei
IPC分类号： C07K16/00
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/00 , C07K2317/30 , C07K2317/524 , C07K2317/526 , C07K2317/72 , C07K2317/90 , C07K2317/94 , C40B30/04 , G01N33/6857 , G01N2333/705 , G01N2500/04
摘要： Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment, that is, little or no binding activity at a physiologic pH. Also described are variant Fc-polypeptides that comprise these variant Fc-fragments. Further described are methods of making and identifying such Fc-fragments and methods for making and using such Fc-polypeptides.
摘要翻译： 本文描述的是变体Fc片段，其在pH 5-6处具有更高亲和力和/或更高结合活性的结合到新生儿Fc受体（FcRn）的环内或附近的插入，并且在一个 生理pH与对照Fc片段相比，即在生理pH下几乎没有或没有结合活性。 还描述了包含这些变体Fc片段的变体Fc-多肽。 进一步描述了制备和鉴定这样的Fc片段的方法以及制备和使用这种Fc-多肽的方法。
-
公开(公告)号：EP2358749A2
公开(公告)日：2011-08-24
申请号：EP09748878.7
申请日：2009-10-08
申请人： Amgen, Inc
发明人： WALKER, Kenneth W. , GEGG, Colin, V., Jr. , HECHT, Randy I. , BELOUSKI, Edward J. , LI, Yue-Sheng , MICHAELS, Mark L. , XU, Jing , ELLISON, Murielle M.
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides comprising extended in vivos half-lives, pharmaceutical compositions comprising FGF21 mutant polypeptides having extended in vivos half lives, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
摘要翻译： 本发明提供编码FGF21突变体多肽的核酸分子，包含在活体半衰期延长的FGF21突变体多肽，包含在活体半衰期延长的FGF21突变体多肽的药物组合物，以及使用这种核酸，多肽或药物治疗代谢紊乱的方法 成分。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.023 秒)
